Notice on Convening the 2025 Annual General Meeting

Earlier from Beijing Wantai Biological Pharmacy Enterprise

• Announcement on Approval Notice of Clinical Trial for Recombinant Trivalent Rotavirus Subunit Vaccine (Escherichia coli)Mar 27
• Announcement on Resignation of Secretary of Board of DirectorsMar 26
• Announcement on Redemption at Maturity of Some Idle Raised Funds Used for Cash Management and Continuing Cash ManagementMar 19
• Announcement on Approval for Clinical Trials of the Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)Mar 17
• Announcement on Plan of Shareholding Reduction by Directors through Call AuctionFeb 10

Later from Beijing Wantai Biological Pharmacy Enterprise

• Announcement on "Corporate Value and Return Enhancement" Action Plan 2026Apr 28
• Announcement on Resolutions of the 2025 Annual General MeetingMay 19
• Announcement on Chairman Acting as Secretary of the Board of DirectorsMay 23
• Announcement on Directors Not Reducing Their Shareholdings and Early Termination of the Shareholding Reduction PlanMay 29
• Announcement on the Completion of National (Excluding Hong Kong, Macao, and Taiwan) Market Access for the Company’s 9-Valent HPV VaccineMay 30